Skip to main content
Late-Breaking Research: PRACTICE MANAGEMENT RESEARCH
Abstract #LB03

Incorporation of a Statewide Cancer Drug Repository Program Within an Integrated Specialty Pharmacy

JHOP - March 2025 Vol 15 Special Feature - HOPA Abstracts
Melisa McKendry, RPh, MSEd; Emily Mackler, PharmD, BCOP; Kimberly Melgarejo, PharmD, MHA; Siobhan Norman

Presenting Authors: Melisa McKendry, RPh, MSEd, The Cancer and Hematology Centers, Grand Rapids, MI; Emily Mackler, PharmD, BCOP, Michigan Oncology Quality Consortium, Michigan Institute for Care Management and Transformation, YesRx, and University of Michigan, Ann Arbor, MI

Co-Authors: Kimberly Melgarejo, PharmD, MHA, The Cancer and Hematology Centers, Grand Rapids, MI; Siobhan Norman, YesRx, Ann Arbor, MI

BACKGROUND: Medication access for patients with cancer has become increasingly challenging as oral anticancer agents have established a prominent position in cancer treatment. Medically integrated specialty pharmacies serve an important role in enhancing patient medication access and in navigating the multiple financial barriers and facilitators of medication access.

OBJECTIVE: To describe the impact that participation in a statewide cancer drug repository (CDR) program has on specialty pharmacy employees and the impact its use has on other medication access resources.

METHODS: This single-center, retrospective analysis was conducted with data from September 2023 to September 2024. In addition, an employee satisfaction survey was completed by specialty pharmacy staff in December 2024. The intervention was participation in a statewide CDR network, YesRx, beginning in September 2023. Our institution had a stand-alone CDR from January 2023 to September 2023 before joining the statewide network. Therein, we describe the utilization of medication access resources, workflow, and employee satisfaction related to YesRx participation.

RESULTS: A total of 19 of 21 (90%) specialty pharmacy employees completed the satisfaction survey. Of those 19, 9 were pharmacy technicians, 9 were pharmacists, and 1 was a pharmacy intern. In all, 12 of the participants reported working within the specialty pharmacy before CDR participation. Of the 12, 5 (42%) participants reported an increase in workload and the remaining 7 (58%) reported no change. In all, 8 of 12 (67%) participants reported an increase in work satisfaction as a result of YesRx participation, and the remaining 4 of the 12 participants reported no change in satisfaction. None of the respondents reported a decrease in satisfaction. All 19 participants recommend CDR participation to other integrated specialty pharmacies. From September 2023 to September 2024, we dispensed a total of 263 prescriptions from the statewide CDR. We found that the use of the CDR did not decrease our utilization of other medication access resources but rather supplemented it. The majority of patients receiving CDR medication did so in conjunction with another resource, and the CDR allowed us to begin therapy in a timelier fashion or allowed us to fill a gap in benefits coverage that would have otherwise resulted in nonadherence.

CONCLUSION: Participation in the statewide CDR network, YesRx, provided a high level of satisfaction for our team members and complemented the current medication access resources.

  1. Zuckerman AD, Mourani J, Smith A, et al. 2022 ASHP survey of health-system specialty pharmacy practice: clinical services. Am J Health Syst Pharm. 2023;80:827-841.
  2. Choi D, Zuckerman AD, Gerzenshtein S, et al. A primer on copay accumulators, copay maximizers, and alternative funding programs. J Manag Care Spec Pharm. 2024;30:883-896.
  3. ASHP Sample Health System Specialty Pharmacy Workforce Stay Interview. Accessed November 19, 2024. www.ashp.org/-/media/9F8416A5472E492C9920003CA44C485E.pdf
  4. YesRx. Accessed November 19, 2024. www.yesrx.org
Related Items
Optimizing Iron Dextran Infusion Protocols to Enhance Efficiency and Patient Throughput in an Outpatient Infusion Center: A Process Improvement Initiative
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Characteristics and Dosing Patterns of US Patients Diagnosed With HR-Positive/HER2-Negative Early Breast Cancer Initiating Abemaciclib at a Lower Dose Than the Approved 150 mg Twice Daily
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Clinical Characteristics and Treatment Persistence in US Patients With HR-Positive/HER2-Negative, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Clinical Outcomes of 2-Dose Tandem Influenza Vaccination Strategy in Patients With Plasma Cell Dyscrasias
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Dexamethasone Versus Tocilizumab for Management of Cytokine Release Syndrome Related to Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Evaluating the Impact of Interactive Ambulatory Care Discussions at an Oncology Center
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Evaluation of a Decentralized Infusion Pharmacist in an Oncology Infusion Clinic of an Academic Medical Center
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Evaluation of Reduced Observation Times for Subcutaneous Administration of Daratumumab and Hyaluronidase in Patients With Multiple Myeloma
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Evaluation of Services Provided by Pharmacists in Addition to Accredited Patient Management Program Responsibilities in a Health-System Specialty Pharmacy
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Hematologic Oral Oncolytics: Adherence, Healthcare Cost, and Utilization
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts